Revelation Biosciences Statistics
Total Valuation
REVB has a market cap or net worth of $4.70 million. The enterprise value is $822,456.
Important Dates
The next estimated earnings date is Friday, August 8, 2025, after market close.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
REVB has 1.53 million shares outstanding.
| Current Share Class | 1.53M |
| Shares Outstanding | 1.53M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +180.32% |
| Owned by Insiders (%) | 1.00% |
| Owned by Institutions (%) | 0.77% |
| Float | 1.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.33 |
| P/TBV Ratio | 1.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.61
| Current Ratio | 3.61 |
| Quick Ratio | 3.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -233.26% and return on invested capital (ROIC) is -82.65%.
| Return on Equity (ROE) | -233.26% |
| Return on Assets (ROA) | -54.68% |
| Return on Invested Capital (ROIC) | -82.65% |
| Return on Capital Employed (ROCE) | -283.54% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.60M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.21% in the last 52 weeks. The beta is -0.08, so REVB's price volatility has been lower than the market average.
| Beta (5Y) | -0.08 |
| 52-Week Price Change | -96.21% |
| 50-Day Moving Average | 4.21 |
| 200-Day Moving Average | 17.07 |
| Relative Strength Index (RSI) | 49.67 |
| Average Volume (20 Days) | 280,250 |
Short Selling Information
The latest short interest is 67,566, so 4.40% of the outstanding shares have been sold short.
| Short Interest | 67,566 |
| Short Previous Month | 152,953 |
| Short % of Shares Out | 4.40% |
| Short % of Float | 4.45% |
| Short Ratio (days to cover) | 0.06 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.17M |
| Pretax Income | -15.90M |
| Net Income | -14.41M |
| EBITDA | -8.14M |
| EBIT | -8.17M |
| Earnings Per Share (EPS) | -$108.79 |
Full Income StatementBalance Sheet
The company has $3.70 million in cash and n/a in debt, giving a net cash position of $3.70 million or $2.41 per share.
| Cash & Cash Equivalents | 3.70M |
| Total Debt | n/a |
| Net Cash | 3.70M |
| Net Cash Per Share | $2.41 |
| Equity (Book Value) | 2.88M |
| Book Value Per Share | 8.97 |
| Working Capital | 2.84M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$18.28 million and capital expenditures $1, giving a free cash flow of -$18.28 million.
| Operating Cash Flow | -18.28M |
| Capital Expenditures | 1 |
| Free Cash Flow | -18.28M |
| FCF Per Share | -$11.91 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
